Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 6, 2011, Pages

  Ardizzone, Sandro ^a   Cassinotti, Andrea ^a   Duca, Piergiorgio ^a   Mazzali, Cristina ^a   Penati, Chiara ^a   Manes, Gianpiero ^a   Marmo, Riccardo ^b   Massari, Alessandro ^a   Molteni, Paola ^a   Maconi, Giovanni ^a   Porro, Gabriele Bianchi ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Unità Operativa Gastroenterologia Polla   (Italy)

Author keywords

Clinical Course; Endoscopy; Inflammatory Bowel Diseases; Mucosal Healing

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; MERCAPTOPURINE; METHYLPREDNISOLONE; PREDNISOLONE; SALICYLIC ACID; STEROID;

ADULT; ARTICLE; COLON MUCOSA; COLON RESECTION; CORTICOSTEROID THERAPY; DISEASE COURSE; ENDOSCOPY; FEMALE; HEALING; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RATING SCALE; ULCERATIVE COLITIS;

EID: 79957452795     PISSN: 15423565     EISSN: 15423565     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.12.028     Document Type: Article

References (27)

1. Kornbluth A., Sachar D. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010, 105:501-523.
2. Bianchi-Porro G., Cassinotti A., Ferrara E., et al. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther 2007, 26:779-794.
3. Rutgeerts P., Vermeire S., Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut 2007, 56:453-455.
4. Wright R., Truelove S.C. Serial biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966, 11:1854-1858.
5. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
6. Froslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
7. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 1955, 2:1041-1048.
8. Oshitani N., Matsumoto T., Jinno Y., et al. Prediction of short-term outcome for patients with active ulcerative colitis. Dig Dis Sci 2000, 45:982-986.
9. Faubion W.A., Loftus E.V., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
10. Ho G.T., Chiam P., Drummond H., et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006, 24:319-330.
11. Truelove S.C., Watkinson G., Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. BMJ 1962, 2:1708-1711.
12. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989, 24(Suppl 170):2-6.
13. Powell-Tuck J., Bown R.L., Lennard-Jones J.E. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978, 13:833-837.
14. Baron J.H., Connell A.M., Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. BMJ 1964, 1:89-92.
15. Langholz E., Munkholm P., Davidsen M., et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994, 107:3-11.
16. Farmer R.G., Easley K.A., Rankin G.B. Clinical patterns, natural history, and progression of ulcerative colitis. A long term follow-up of 1116 patients. Dig Dis Sci 1993, 38:1137-1146.
17. Hoie O., Wolters F.L., Riis L., et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007, 132:507-515.
18. Goligher J.C., Hoffman D.C., de Dombal F.T. Surgical treatment in severe attacks of ulcerative colitis, with special reference to the advantage of early operation. BMJ 1970, 4:703-706.
19. Kane S., Lu F., Kornbluth A., et al. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2009, 15:796-800.
20. Riley S.A., Mani V., Goodman M.J., et al. Why do patients with ulcerative colitis relapse?. Gut 1990, 31:179-183.
21. Leo S., Leandro G., Di Matteo G., et al. Ulcerative colitis in remission: is it possible to predict the risk of relapse?. Digestion 1989, 44:217-221.
22. Hoie O., Wolters F., Riis L., et al. Ulcerative colitis: patient characteristics may predict 10-year disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007, 102:1692-1701.
23. Hoie O., Wolters F., Riis L., et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007, 132:507-515.
24. Bitton A., Peppercorn M.A., Antonioli D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13-20.
25. Kuriyama M., Kato J., Fujimoto T., et al. Risk factors and indications for colectomy in ulcerative colitis patients are different according to patient's clinical background. Dis Colon Rectum 2006, 49:1307-1315.
26. Bottini N., Gloria-Bottini F., Lucarini N., et al. Inflammatory bowel disease: are there gender differences in the genetics of signal transduction?. A preliminary study of cytosolic low molecular weight protein tyrosine phosphatase. Dis Markers 2000, 16:163-166.
27. Gloria-Bottini F., Bottini N., Renzetti G., et al. ACP1 and Th class of immunological disease: evidence of interaction with gender. Int Arch Allergy Immunol 2007, 143:170-176.